Goutham Narla

Goutham Narla, MD, PhD, is an Associate Professor in the Department of Medicine and Division of General Medical Sciences, and an Assistant Professor in the Department of Pathology at Case Western Reserve University School of Medicine. He is also a member of the Developmental Therapeutics Program at the Case Comprehensive Cancer Center. His research focuses on protein phosphatase 2A (PP2A) dysfunction in cancer, including mechanisms of PP2A dysregulation in high-grade uterine, pancreatic, and ovarian cancers, as well as translational applications of PP2A-activating small molecules for cancer therapy.

Dr. Narla's work integrates molecular pharmacology, genetic engineering, and preclinical models (e.g., the SRG Rat® xenograft system) to study tumor microenvironment interactions and develop targeted therapies. His research also explores PP2A's role in non-oncologic conditions like thoracic aortic disease and liver transplantation.

• Key Scientific Focus: PP2A-based drug discovery, genetic cancer drivers, and tumor microenvironment engineering
• Notable Projects: Development of PP2A molecular glues for uterine cancer, SRG Rat® xenotransplantation model optimization, and integrated stress response modulation in cancer
• Grants: Supported by NIH and industry collaborations (unspecified in text)

His articles highlight PP2A's role in KRAS-driven pancreatic cancer, mutant PPP2R1A-driven uterine tumors, and B56-PP2A heterotrimer modulation for therapy resistance. He has pioneered SRG Rat® as a platform for patient-derived xenograft studies.

• Major Awards: Not explicitly listed in provided text
• Labs/Teams: Developmental Therapeutics Program (Case Cancer Center), PP2A Pharmacology Lab